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the retest of different components ranged from 0.81 to 0.99. All hypothesized cor-
relationswith convergentmeasureswere significant (r0.40; p0.01), and theMDS
SS-5 discriminated between LOT-R tertiles (F24.6, p0.001), SRH between doctor
visits (F8.0 p0.01) and TIBI between illness days (F14.9, p0.001).
CONCLUSIONS: Consistent with the results found in the United States, the ENSEM-
BLE MDS was observed to have adequate reproducibility, appropriate convergent
validity and to significantly discriminate between known groups outside the
United States.
QU3
PSYCHOMETRICS OF THE ACTINIC KERATOSIS RISK QUESTIONNAIRE: A RISK
ASSESSMENT INSTRUMENT
Balkrishnan R1, Kulkarni AS2, Gatwood J1, Anderson RT3, Narahari S4, Landis E4,
Feldman SR4
1University of Michigan, Ann Arbor, MI, USA, 2Leo Pharma, Parsippany, NJ, USA, 3Pennsylvania
State University, Hershey, PA, USA, 4Wake Forest University School of Medicine, Winston-Salem,
NC, USA
OBJECTIVES:Actinic keratosis is a highly prevalent epidermal neoplastic condition
among people in the United States with fair skin and a history of long term UV
exposure. A new self-assessment survey-based tool was developed to help people
assess their risk of either having or developing actinic keratosis. The objective of
this research was to assess detailed psychometrics of the developed survey.
METHODS: A test questionnaire, comprised of 10 items, was initially developed
using data obtained from subjects in routine clinical practice and interviews with
dermatologists. The instrument was administered along with established and val-
idated skin health assessment instruments (DLQI and Skindex-16) to 150 subjects
prior to them being given a diagnosis of actinic keratosis by the dermatologist. A
total of 75 subjects with a clinical diagnosis of actinic keratosis and 75 age/sex
matched controls without actinic keratosis formed the sample for this study. Ex-
ploratory factor analyses, item response theory analyses, and other psychometric
techniques were used to assess the reliability and validity of the Actinic Keratosis
Risk Questionnaire (AKRQ). RESULTS: The final AKRQ instrument assessed was
refined based on the results of exploratory factor analysis and item response tech-
niques, ultimately limiting the scale to six items. The resulting instrument had
good internal consistency (Chronbachs alpha  0.70) and correlations with other
validatedmeasures of skin quality of life (rho0.596with the Skindex-16 and rho
0.429 with the DLQI, P0.01). The sensitivity, specificity, positive and negative pre-
dictive values of the AKRQ was found to be 69.3%, 73.3%, 72.2% and 70.5%
respectively. CONCLUSIONS: The AKRQ is a reliable and valid tool whichmay help
patients self-assess their risk of either having or developing actinic keratosis based
on their skin health-related behavior and quality of life symptomatology.
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OBJECTIVES: Patient satisfaction is a critical component of health care perfor-
mance in all settings including pharmacy-provided services. Our study aimed to
assess the validity and reliability of a newly developed survey used to evaluate
patient satisfaction of an employer-sponsored medication therapy management
(MTM) program provided in an independent pharmacy setting. METHODS: This
exploratory study used a cross-sectional design. The survey was developed using
three previous instruments and using input from practicing pharmacists. The in-
strument consisted of three sections (experience with the pharmacist, pharmacy,
and pharmacy staff). Face validity was assessed by a review panel of practicing
pharmacists and researchers. Final survey consisted of thirty-four items. A five-
point Likert scale (1  strongly disagree to 5  strongly agree) was used. Data was
collected over a one-year period and analyzed using SPSS v. 17.0. Construct validity
was assessed by an exploratory factor analysis using the principal components
method and a varimax rotation. Internal consistency reliability was tested using
Cronbach’s alpha. RESULTS: Factor analysis with varimax rotation (n 171) re-
sulted in five dimensions. Upon assessment, we labeled the factors as Experience
with the Pharmacist, Experience with the Pharmacy, Experience with the Phar-
macy Staff, Satisfaction of Pharmacy Care, and Prescription Promptness. The KMO
measure of sampling adequacy was .954. Experience with the pharmacist ac-
counted for 62.86% of the variance with the eigenvalue of 21.373. Cronbach’s alpha
for the five dimensions was found to be .977, .927, .975, .962, .868, respectively.
CONCLUSIONS: Results indicate the survey demonstrates validity and reliability.
With health care moving towards a more patient-centered approach and an in-
creasing need to have patients evaluate services provided, the instrument devel-
oped for this study could serve as a valuable tool. Pharmacists may utilize this tool
to assess their ownMTMprograms. However, additional testing in other pharmacy
settings is recommended for further assessment.
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OBJECTIVES: As Comparative Effectiveness Research (CER) gains a stronger foot-
hold in the US Healthcare systemwe turn our sights on the market implications of
conducting “real-world” studies of the effectiveness and safety of a clinical inter-
vention to guide evidence-based practice. Barriers to assimilation of CER in clinical
decision-making may be shaped by market factors such as coverage, reimburse-
ment, and generic availability. This analysis aims to determine what, if any,
changes in prescribing patterns might have been precipitated by the findings of
CER studies and examines the possible causes of such changes with respect to
differences in efficacy, safety and price.METHODS:We examined prescribing pat-
terns for drugs included in six Comparative Effectiveness Research (CER) studies
–one neuroscience, one diabetes and four cardiovascular – before and after publi-
cation. Our analysis separately tracked new and refill prescriptions for the same
number of quarterly intervals before and after publication of the studies analyzed,
ending with Q2 (June) 2011. Drug prescription volumes and average wholesale
prices (except where noted) were obtained using SDI Health’s Vector One National
Audit. Metrics were compared in the quarters before and after study publication.
Statistical significance was defined as p0.05. Analyses were performed using Mi-
crosoft Excel, two-tailed t-test. RESULTS: Drugs included in three of the six CER
studies- neuroscience, diabetes and cardiovascular- showed significant changes in
new, refill or total prescriptions of the drugs studies that were consistent with the
published findings (i.e. positive changes following positive findings).
CONCLUSIONS: Factors, in addition to the studies’ findings themselves, that could
have contributed to the observations include pricing of the drugs compared in the
studies and generic availability.We hypothesize that factors impacting adoption of
CER results in clinical practice include the number of patients enrolled and the
method of dissemination of results.
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OBJECTIVES: During 2009-2011 major health care reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the United
States, AMNOG inGermany, HSPT in France, KVG in Switzerland andNHSproposed
reform in the UK. These reforms havemajor implications on pricing,market access
and HEOR strategy for drug and device products. METHODS: To understand the
implications of these trends, we analyzed 2009-2011 reform bills and proposed
changes worldwide. Additionally, we interviewed public and private payers, key
opinion leaders and payer-influencers to understand implications of these reforms
on drug and device manufacturers. Stakeholders ranked various data collection
methods on a scale of 1-10 (1-least important and 10-most important). RESULTS:
The global healthcare landscape is expected to undergo significant change during
2012-2016. In the United States, government will play increased role as a single
payer, especially with?Medicare, Medicaid and CHIP programs? which will cover
114 million Americans, at a cost of $784 billion. In Germany, AMNOG bill marked
the end of free drug pricing andwould lead to increased insurance premiums (now
15.5% of wages). In the United Kingdom, NHS has proposed to replace PCTs with
500-1000 GP-led consortia and use value-based pricing for expensive drugs and
devices. Randomized controlled trial, budget impactmodel and systematic reviews
—ranked highest (7.5-9.1) among payers. Overall, payers view that in the future,
health economic assessments would play critical role in pricing, coverage and
reimbursement of branded products. CONCLUSIONS: This analysis shows that
global health care landscape is expected to undergo significant change during 2012-
2016. Discussions with payers, KOLs and payer-influencers highlights increased
importance of HEOR data in the future.
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OBJECTIVES: After the patent expires for a branded pharmaceutical, generic drug
companies generally sell bioequivalent versions of the drug, leading to lower
prices. Considering more drugs over a longer period of time than previously in the
literature, the objectiveswere to (1) describe the trends in branded and generic drug
prices post-entry; and (2) estimate the effects of drug, firm, and market character-
istics on branded and generic prices.METHODS: The primary data source was the
Medicaid State Drug Utilization Data maintained by the Centers for Medicare &
Medicaid Services. Quarterly utilization and expenditure data from 1991-2008were
extracted for 83 drugs that experienced initial generic entry between 1992 and 2004.
A relative price for a specific drug, firm, and quarter was constructed as Medicaid
reimbursement per unit divided by average reimbursement per unit of the branded
drug the year before entry. Autoregressive fixed-effects and random-effects mod-
els were estimated to explain relative drug price. RESULTS: For the 83 drugs, prices
for 229 firmswere followed from the first quarter of generic entry until 2008. Twelve
quarters after generic entry, 17% of drugs had average relative generic price less
than 50% of the original branded price. The number of firms had a statistically
significant (p0.01) negative effect on price. For each additional firm manufactur-
ing the generic drug, average price was estimated to fall by 8 percentage points.
Higher demand had a statistically significant (p0.01) positive effect. No statisti-
cally significant price premium for either early entry or firm size was found. Inject-
able drugs had prices that fell less (p0.01) than other drugs. CONCLUSIONS: Re-
sults are consistent with earlier studies showing that branded-drug prices rise and
generic drug prices fall as more generic firms enter. However, this fall is not as
strong for injectable drugs or for drugs with high demand.
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